ARUP's Laboratory Test Directory
| 0070234: Prostate Specific Antigen, Total - Medicare Screening |
| Test Mnemonic: PSA SCN | |
|
Methodology: Electrochemiluminescent Immunoassay
Performed: Sun-Sat Reported: Within 24 hours |
| Specimen Required: | |
|
Collect: One 4 mL SST or PST. Also acceptable: green (sodium or lithium heparin), lavender (EDTA), or pink (K2EDTA).
Transport: 1 mL serum or plasma, frozen. (Min: 0.5 mL) Unacceptable Conditions: Hemolyzed samples. Stability: Ambient: 8 hours; Refrigerated: 5 days; Frozen: 6 months |
|
| Reference Interval: |
| 0.0-4.0 ng/mL |
| Interpretive Data: | |
|
The Roche Modular E170 PSA method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche Modular E170 PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche Modular E170 PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma.
|
| Note: | |
| This test should be ordered for screening purposes for Medicare patients only. |
| CPT Code(s): | |
| G0103 |